{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lactoyl glutathione lyase : Questions médicales les plus fréquentes",
"headline": "Lactoyl glutathione lyase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lactoyl glutathione lyase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-19",
"dateModified": "2025-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lactoyl glutathione lyase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Carbon-sulfur lyases",
"url": "https://questionsmedicales.fr/mesh/D013437",
"about": {
"@type": "MedicalCondition",
"name": "Carbon-sulfur lyases",
"code": {
"@type": "MedicalCode",
"code": "D013437",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.520.300"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lactoyl glutathione lyase",
"alternateName": "Lactoylglutathione Lyase",
"code": {
"@type": "MedicalCode",
"code": "D007791",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yu-Zhong Zhang",
"url": "https://questionsmedicales.fr/author/Yu-Zhong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "College of Marine Life Sciences, Frontiers Science Center for Deep Ocean Multispheres and Earth System, Ocean University of China, Qingdao 266003, China."
}
},
{
"@type": "Person",
"name": "Julie D Saba",
"url": "https://questionsmedicales.fr/author/Julie%20D%20Saba",
"affiliation": {
"@type": "Organization",
"name": "Children's Hospital Oakland Research Institute, University of California, San Francisco Benioff Children's Hospital Oakland, Oakland, CA 94609 jsaba@chori.org."
}
},
{
"@type": "Person",
"name": "Lidia de Bari",
"url": "https://questionsmedicales.fr/author/Lidia%20de%20Bari",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies-CNR, Via G. Amendola 122/O, 70126 Bari, Italy."
}
},
{
"@type": "Person",
"name": "Marissa N Trujillo",
"url": "https://questionsmedicales.fr/author/Marissa%20N%20Trujillo",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Erin Q Jennings",
"url": "https://questionsmedicales.fr/author/Erin%20Q%20Jennings",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Can an End-to-End Telesepsis Solution Improve the Severe Sepsis and Septic Shock Management Bundle-1 Metrics for Sepsis Patients Admitted From the Emergency Department to the Hospital?",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36248316",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/CCE.0000000000000767"
}
},
{
"@type": "ScholarlyArticle",
"name": "\"There are solutions and I think we're still working in the problem\": The limitations of decriminalization under the good Samaritan drug overdose act and lessons from an evaluation in British Columbia, Canada.",
"datePublished": "2022-05-10",
"url": "https://questionsmedicales.fr/article/35561485",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugpo.2022.103714"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metabolite Profiling of Hydroponic Lettuce Roots Affected by Nutrient Solution Flow: Insights from Comprehensive Analysis Using Widely Targeted Metabolomics and MALDI Mass Spectrometry Imaging Approaches.",
"datePublished": "2024-09-21",
"url": "https://questionsmedicales.fr/article/39337645",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms251810155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Implementation of collaborative care for depression in VA HIV clinics: Translating Initiatives for Depression into Effective Solutions (HITIDES): protocol for a cluster-randomized type 3 hybrid effectiveness-implementation trial.",
"datePublished": "2024-09-16",
"url": "https://questionsmedicales.fr/article/39285308",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s43058-024-00639-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Solution for the External Contour Changes in Cone Beam Computed Tomography-Guided On-demand Online Adaptive Radiotherapy for a Patient With Very Advanced Head and Neck Cancer: A Technical Case Report.",
"datePublished": "2024-08-26",
"url": "https://questionsmedicales.fr/article/39328634",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.67804"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lyases",
"item": "https://questionsmedicales.fr/mesh/D008190"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carbon-sulfur lyases",
"item": "https://questionsmedicales.fr/mesh/D013437"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lactoyl glutathione lyase",
"item": "https://questionsmedicales.fr/mesh/D007791"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lactoyl glutathione lyase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lactoyl glutathione lyase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lactoyl glutathione lyase",
"description": "Comment diagnostiquer une déficience en lactoyl glutathione lyase ?\nQuels tests sont utilisés pour évaluer l'activité de cette enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des biomarqueurs associés à cette enzyme ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles liés à cette enzyme ?",
"url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Solutions&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lactoyl glutathione lyase",
"description": "Quels sont les symptômes d'une déficience en lactoyl glutathione lyase ?\nLa déficience peut-elle causer des problèmes cutanés ?\nY a-t-il des symptômes digestifs associés ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on observer des symptômes psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Solutions&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lactoyl glutathione lyase",
"description": "Comment prévenir les complications liées à cette enzyme ?\nY a-t-il des tests de dépistage recommandés ?\nLes antioxydants peuvent-ils prévenir des problèmes ?\nEst-il important de gérer le stress ?\nLes vaccinations sont-elles importantes ?",
"url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Solutions&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lactoyl glutathione lyase",
"description": "Quels traitements sont disponibles pour la déficience en lactoyl glutathione lyase ?\nLa thérapie génique est-elle une option ?\nDes changements alimentaires peuvent-ils aider ?\nY a-t-il des médicaments spécifiques à éviter ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Solutions&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lactoyl glutathione lyase",
"description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle affecter le système immunitaire ?\nY a-t-il des risques de maladies chroniques ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications potentielles ?",
"url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Solutions&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lactoyl glutathione lyase",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque ?\nY a-t-il des maladies associées à ce risque ?\nLe mode de vie influence-t-il le risque ?\nLes facteurs environnementaux sont-ils significatifs ?",
"url": "https://questionsmedicales.fr/mesh/D007791?mesh_terms=Solutions&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en lactoyl glutathione lyase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent confirmer la déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité de cette enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de stress oxydatif, comme la fatigue ou des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à cette enzyme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de glutathion et de lactate peuvent être des biomarqueurs."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles liés à cette enzyme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en lactoyl glutathione lyase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, troubles neurologiques, et susceptibilité accrue aux infections."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle causer des problèmes cutanés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées et une sensibilité accrue peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes digestifs associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles digestifs comme des nausées peuvent être présents."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les jeunes enfants."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes psychologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de l'humeur et de l'anxiété peuvent être liés à cette déficience."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées à cette enzyme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain et une alimentation équilibrée peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dépistage génétique peuvent être recommandés pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les antioxydants peuvent-ils prévenir des problèmes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une consommation adéquate d'antioxydants peut réduire le stress oxydatif."
}
},
{
"@type": "Question",
"name": "Est-il important de gérer le stress ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress est cruciale pour maintenir une bonne santé cellulaire."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir les infections chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la déficience en lactoyl glutathione lyase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments de glutathion et des antioxydants peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible."
}
},
{
"@type": "Question",
"name": "Des changements alimentaires peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut soutenir la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques à éviter ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments oxydants doivent être évités pour réduire le stress oxydatif."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés selon la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette déficience ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections récurrentes et des troubles neurologiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle affecter le système immunitaire ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies chroniques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un stress oxydatif accru peut contribuer à des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications potentielles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers avec des professionnels de santé sont essentiels pour surveiller les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et des expositions environnementales peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants sont plus susceptibles de présenter des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des maladies associées à ce risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques peuvent être liées à un risque accru de déficience."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de complications liées à cette enzyme."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut augmenter le risque de déficience."
}
}
]
}
]
}
Early detection and treatment for sepsis patients are key components to improving sepsis care delivery and increased The Severe Sepsis and Septic Shock Management Bundle (SEP-1) compliance may correla...
We assessed the impact of implementing a partially automated end-to-end sepsis solution including electronic medical record-linked automated monitoring, early detection, around-the-clock nurse navigat...
After a "surveillance only" training period between September 3, 2020, and October 5, 2020, the automated end-to-end sepsis solution intervention period occurred from October 6, 2020, to January 1, 20...
SEP-1 compliance during the "surveillance only" period compared to the intervention period....
During the intervention period, 56,713 patients presented to the five ERs; 20,213 (35.6%) met electronic screening criteria for potential sepsis; 1,233 patients had a primary diagnosis of sepsis, pres...
During an 11-week period of sepsis screening, monitoring, and teleconsultation in 5 EDs, SEP-1 compliance improved significantly compared with institutional SEP-1 reporting metrics and to a "surveilla...
Drug prohibition has been associated with increased risk of overdose. However, drug prohibition remains the dominant drug policy, including in Canada with the Controlled Drugs and Substances Act. In 2...
We conducted an evaluation of the GSDOA in British Columbia, Canada that included one-on-one interviews with people who use illicit drugs (PWUD), to determine peoples' experiences and perceptions surr...
We identified limitations of the GSDOA at overdose events; key themes and concerns causing PWUD to hesitate to or avoid contacting emergency medical services included drug confiscation, the thin line ...
Our findings are pertinent in light of many jurisdictions across the world considering dejure decriminalization, including BC and Vancouver. The GSDOA and associated limitations that emerged in our ev...
Root morphology, an important determinant of nutrient absorption and plant growth, can adapt to various growth environments to promote survival. Solution flow under hydroponic conditions provides a me...
Depression is the most diagnosed mental health condition among people living with HIV. Collaborative care is an effective intervention for depression, typically delivered in primary care settings. The...
This hybrid type-3 effectiveness-implementation trial examines the implementation and effectiveness of HITIDES in 8 VHA HIV clinics randomly assigned to one of two implementation arms. Each arm uses a...
Preliminary work identified implementation strategies acceptable to veterans living with HIV and HIV care providers; however, the effectiveness and cost of these strategies are unknown. While the depr...
ClinicalTrials.gov ID: NCT05901272, Registered 10 May 2023, https://clinicaltrials.gov/study/NCT05901272....
This article presents a case of a patient with advanced head and neck cancer, characterized by a large and protruding tumor. The patient was treated with an innovative on-demand online adaptive radiot...
The peritoneal solute transport rate (PSTR) tends to increase over time in some patients undergoing peritoneal dialysis (PD), potentially leading to ultrafiltration (UF) failure. Previous case reports...
The study involved 14 continuous ambulatory peritoneal dialysis (CAPD) patients with high/high-average transport rate. Two groups were randomly assigned different treatment sequences: one group underw...
Short-term peritoneal rest (daily IPD) significantly reduced PSTR, with a decrease in the dialysate:plasma creatinine ratio from 0.71 ± 0.05 to 0.65 ± 0.07 (...
In PD patients with high and high-average transport, a 4-week period of short-term peritoneal rest by switching from CAPD to IPD (without long dwell) can lead to reductions in PSTR and increases in UF...
Two-dimensional metal-organic frameworks (2D MOFs) hold great promise as electrochemically active materials. However, their application in MOF nanocomposite electrodes in solution engineering is limit...
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children around the world. The post-pandemic era has resulted in a notable increase in reported cases of...
APV20002 was a multicenter, international, open-label study that began in 2003 investigating the pharmacokinetics, efficacy, and safety of ritonavir-boosted fosamprenavir (FPV/r) oral solution (OS) in...
In some studies, the peritoneal solute transfer rate (PSTR) through the peritoneal membrane has been related to an increased risk of mortality. It has been observed in the literature that those patien...
A retrospective cohort study was carried out at RTS Colombia in the period between 2007 and 2017. In total, there were 8170 incident patients older than 18 years, who had a Peritoneal Equilibration Te...
Patients were classified into four categories based on the PET result: Slow/Low transfer (16.0%), low average (35.4%), high average (32.9%), and High/Fast transfer (15.7%). During follow-up, with a me...
When evaluating the etiological relationship between the type of peritoneal solute transfer rate and overall mortality and survival of the technique using a competing risk model, we found no etiologic...